Drug Trial News

RSS

KaloBios’ KB001 shows promise against Pa pneumonia

Phase 2a trial results with KB001 suggest the recombinant, human PEGylated monoclonal antibody fragment, under development by KaloBios Pharmaceuticals, Inc. and Sanofi Pasteur, offers potential as an alternative to antibiotics for preventing or reducing pneumonias in mechanically ventilated intensive care unit (ICU) patients heavily colonized with Pseudomonas aeruginosa (Pa).

26 Jun 2012

Experimental medication helps overweight patients with diabetes shed pounds

An experimental drug helped significantly more overweight patients with diabetes shed pounds, compared with placebo, a new study finds. The results will be presented Saturday at The Endocrine Society's 94th Annual Meeting in Houston.

26 Jun 2012

CytRx achieves key milestone in advancing tamibarotene Phase 2b trial for NSCLC

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced the recommendation by the Data Safety Monitoring Board (DSMB) to continue with the global Phase 2b clinical trial with tamibarotene in combination with chemotherapeutical agents as a first-line treatment for patients with advanced non-small-cell lung cancer.

26 Jun 2012

Sinovac provides update on EV71 vaccine Phase III trial on HFMD

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, today provided an update on its Phase III clinical trial progress and commercialization preparation for its proprietary inactivated Enterovirus 71 (EV71) vaccine against hand, foot and mouth disease (HFMD).

26 Jun 2012

Standard aspirin dose may not protect diabetics against blood clots

Many patients with type 2 diabetes may be aspirin resistant. That means the standard aspirin dose may not protect them against blood clots that cause heart attacks and strokes among diabetics, a new clinical study finds. The results will be presented Sunday at The Endocrine Society's 94th Annual Meeting in Houston.

25 Jun 2012

Degludec effectively lowers blood glucose with lower risk for hypoglycemia

An experimental insulin drug prevented low blood sugar among diabetic patients more often than a popular drug on the market, a new study finds. The results will be presented Sunday at The Endocrine Society's 94th Annual Meeting in Houston.

25 Jun 2012

NIH awards Sirnaomics SBIR grant for developing STP705 siRNA wound healing product

Sirnaomics, Inc. announced today that the company has been awarded another NIH SBIR grant for developing its small interfering RNA (siRNA) therapeutic product STP705 to improve skin wound healing with minimized scar formation.

25 Jun 2012

Neuralstem commences dosing in NSI-189 Phase Ib trial for major depressive disorder

Neuralstem, Inc. announced that the first patients were dosed in Phase Ib of its ongoing trial to test the safety of NSI-189 in the treatment of major depressive disorder (MDD).

25 Jun 2012

Positive results from Lexicon’s LX4211 Phase 2b trial on type 2 diabetes

Lexicon Pharmaceuticals, Inc., announced today that LX4211, an investigational, oral, dual inhibitor of sodium glucose transporters 1 and 2 (SGLT1 and SGLT2), showed substantial, dose-dependent, statistically-significant reductions in hemoglobin A1c (HbA1c) in a Phase 2b trial in patients diagnosed with poorly-controlled type 2 diabetes who were concurrently treated with metformin, an established diabetes therapy.

25 Jun 2012

Study reinforces importance of educating parents and other caregivers of children with food allergy

A team of researchers from Mount Sinai School of Medicine and four other institutions have found that young children with documented or likely allergies to milk and/or eggs, whose families were instructed on how to avoid these and other foods, still experienced allergic reactions at a rate of almost once per year. Of severe cases, less than a third received epinephrine, a medication used to counter anaphylaxis, a life-threatening allergic condition.

25 Jun 2012

Deferasirox reduces elevated iron levels in patients with myelodysplastic syndrome

Researchers at Moffitt Cancer Center and colleagues at six other institutions have recently tested a treatment for patients with myelodysplastic syndrome, or MDS, a blood-related malignancy that involves the ineffective production of blood cells, leaving patients anemic and in need of frequent blood transfusions. Because the body has no natural means to reduce iron that accumulates from repeated transfusions, patients' organs can become iron overloaded, leading to heart failure, liver injury, susceptibility to infection, and other complications.

23 Jun 2012

Genentech's Perjeta helps people with HER2-positive metastatic breast cancer live longer

Genentech, a member of the Roche Group, announced today that people with HER2-positive metastatic breast cancer (mBC) lived significantly longer (overall survival) when treated with the combination of Perjeta (pertuzumab), Herceptin (trastuzumab) and docetaxel chemotherapy, compared to Herceptin and docetaxel chemotherapy alone in the Phase III CLEOPATRA study.

23 Jun 2012

AbGenomics raises $11 million in current financing round

AbGenomics International announced today that it has raised $11 million in current financing round. It brings total investment in AbGenomics to approximately $52 million since its inception in 2000.

23 Jun 2012

Alexza resubmits ADASUVE NDA to U.S. FDA

Alexza Pharmaceuticals, Inc. announced today that it has resubmitted its ADASUVE New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in response to a Complete Response Letter (CRL) received in May 2012.

22 Jun 2012

Shanghai Institutes of Preventative Medicine, Gentris sign MOU to advance personalized medicine

Gentris Corporation, a global leader in the application of genomic biomarkers to clinical studies, announced today that it has signed a Memorandum of Understanding with the Shanghai Institutes of Preventative Medicine to advance global personalized medicine.

22 Jun 2012

Aeterna Zentaris announces perifosine Phase 1 trial on neuroblastoma

Aeterna Zentaris Inc. today announced that Phase 1 trial results for its oral PI3K/Akt inhibitor, perifosine, showed the drug's activity against chemo-resistant and radio-resistant neuroblastoma, while allowing good quality of life and sparing vital organs. Neuroblastoma is a type of childhood cancer which usually begins in nerve tissues.

22 Jun 2012

Iroko announces results from diclofenac Phase 3 study on post-surgical pain

Iroko Pharmaceuticals, LLC today announced Phase 3 study results that showed patients treated with the company's novel, submicron particle, lower-dose diclofenac (18mg and 35mg), a non-steroidal anti-inflammatory drug (NSAID), experienced significant pain relief post surgery compared with placebo>0.01 and P<0.001 respectively).

22 Jun 2012

Data from MAP Pharmaceuticals’ LEVADEX clinical studies to be presented at AHS meeting

MAP Pharmaceuticals, Inc. today announced that the Company will present data on LEVADEX (formerly MAP0004), an orally inhaled investigational drug for the acute treatment of migraine, at the 54th Annual Scientific Meeting of the American Headache Society (AHS) in Los Angeles, CA, June 21-24, 2012.

22 Jun 2012

Study to test NAC and aspirin for people diagnosed with bipolar disorder

A commonly available pharmaceutical drug with anti-inflammatory properties and a nutritional supplement thought to have antioxidant effects are now being tested at The University of Texas Health Science Center at Houston (UTHealth) as add-on therapies for people diagnosed with bipolar disorder.

21 Jun 2012

Levodopa/carbidopa intestinal gel reduces 'off' time in people with advanced PD

A new delivery method for levodopa/carbidopa, a common dual-drug Parkinson's disease (PD) regimen, significantly improved the duration of the drugs' effectiveness in people with advanced PD, according to research by Mount Sinai School of Medicine.

21 Jun 2012